Effects of Mesenchymal Stem Cell Transplantation on Cerebrospinal Fluid Biomarkers in Progressive Multiple Sclerosis

Panayiota Petrou, Ibrahim Kassis, Ariel Ginzberg, Michelle Hallimi, Dimitrios Karussis, Panayiota Petrou, Ibrahim Kassis, Ariel Ginzberg, Michelle Hallimi, Dimitrios Karussis

Abstract

Background: Neurofilament light chains (NF-L) were shown to serve as a reliable biomarker of neurodegeneration in multiple sclerosis (MS). The chemokine receptor CXCL13 was shown to correlate with CNS inflammatory activity and to predict the future progression of MS.

Objective: To evaluate the levels of NF-L and CXCL13 in the cerebrospinal fluid (CSF) following treatment with mesenchymal stem cells (MSC) in patients with progressive MS.

Methods: The CSF samples were obtained from 48 patients with progressive MS who participated in a double-blind randomized phase II clinical trial that tested the effects of intrathecal (IT) or intravenous (IV) transplantation of mesenchymal stem cells (MSC), at baseline (before the first injection of the MSC) and at 6 months following treatment with MSC, or sham treatment. The CSF specimens were tested in a blinded way, using a single-molecule array (SIMOA) technique.

Findings: The CSF levels of NF-L were significantly lower at 6 months following treatment with MSC-IT when compared with the baseline, pre-treatment measurements (P = .026, Wilcoxon paired test). Nine out of 15 tested patients in the MSC-IT group had a reduction in NF-L levels of more than 50% (median decrease: -4449 pg/mL) when compared with 5/15 in the MSC-IV group (median decrease: -151 pg/mL) and 1/15 in the placebo group (median increase: +2450 pg/mL) (P = .001 for MSC-IT vs. placebo, chi-square test). CXCL13 levels were also reduced at 6 months following MSC-IT treatment but not to a statistically significant level.

Conclusions: Our findings indicate possible neuroprotective effects of MSC transplantation in patients with MS.

Clinical trial registration: NCT02166021.

Keywords: mesenchymal stem cells; multiple sclerosis; neurodegeneration; neurofilaments (NF-L); neuroprotection; stem cells.

© The Author(s) 2022. Published by Oxford University Press.

Figures

Figure 1.
Figure 1.
CSF levels of NF-L (A) and CXCL13 (B) at baseline and 6 months following intrathecal (MSC-IT) or intravenous (MSC-IV) treatment with MSC. Abbreviations: CSF, cerebrospinal fluid; MSC, mesenchymal stem cells; NF-L, neurofilament light chains.

References

    1. Cairns NJ, Lee VM, Trojanowski JQ.. The cytoskeleton in neurodegenerative diseases. J Pathol. 2004;204(4):438-449.
    1. Williams T, Zetterberg H, Chataway J.. Neurofilaments in progressive multiple sclerosis: a systematic review. J Neurol. 2021;268:3212-3222.
    1. Chitnis T, Gonzalez C, Healy BC, et al. . Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis. Ann Clin Transl Neurol. 2018;5(12):1478-1491.
    1. Disanto G, Barro C, Benkert P, et al. ; Swiss Multiple Sclerosis Cohort Study Group . Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81(6):857-870.
    1. Håkansson I, Tisell A, Cassel P, et al. . Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis. Eur J Neurol. 2017;24(5):703-712.
    1. Novakova L, Zetterberg H, Sundström P, et al. . Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology. 2017;89(22):2230-2237.
    1. Khademi M, Kockum I, Andersson ML, et al. . Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler. 2011;17(3):335-343.
    1. Rice CM, Kemp K, Wilkins A, Scolding NJ.. Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases. Lancet. 2013;382(9899):1204-1213.
    1. Scolding NJ, Pasquini M, Reingold SC, Cohen JA; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis . Cell-based therapeutic strategies for multiple sclerosis. Brain. 2017;140(11):2776-2796.
    1. Cohen JA, Imrey PB, Planchon SM, et al. . Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Mult Scler. 2018;24(4):501-511.
    1. Connick P, Kolappan M, Crawley C, et al. . Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 2012;11(2):150-156.
    1. Petrou P, Kassis I, Levin N, et al. . Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Brain. 2020;143(12):3574-3588.
    1. Rissin DM, Kan CW, Campbell TG, et al. . Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol. 2010;28(6):595-599.
    1. Baldassari LE, Planchon SM, Bermel RA, et al. . Serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantation. Mult Scler J Exp Transl Clin. 2019;5(4):2055217319887198.
    1. Uccelli A, Pistoia V, Moretta L.. Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol. 2007;28(5):219-226.
    1. Magliozzi R, Howell O, Vora A, et al. . Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007;130(Pt 4):1089-1104.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다